Faced with a steep patent cliff and a shrinking pipeline of new drugs to replace revenues associated with former blockbusters, the pharma industry has updated and enhanced its drug development models with an emphasis on partnerships, and universities are high on their list. The pace of change has accelerated as pharma companies struggle not only with poor pipeline performance, but also increasing reimbursement, regulatory and economic pressures.
The result for a growing number of TTOs has been the initiation of lucrative new partnership models that take advantage of respective strengths and overcome historical barriers. These new partnerships, if successfully executed, will create massive returns for years to come in terms of both more rapid and successful translation of research and a strong stream of revenues (and jobs) linked to a long-term industry-university drug development engine.
To help ensure your university and TTO benefit from this historical shift and the opportunities that come with it, Technology Transfer Tactics’ Distance Learning Division has scheduled a critical program featuring Alex Fayne, Chief Operating Officer of Pfizer’s Centers for Therapeutic Innovation, and Nurjana Bachman, PhD, Business Development Manager for the Technology & Innovation Development Office of Children’s Hospital Boston.
How Your University’s Innovations
Can Become a Fixture in Big Pharma’s Pipeline
In 90 minutes, this session will discuss the changing dynamics between pharma and academia, cite examples of new partnering models, and offer unique insights into Pfizer’s partnership efforts taking place within its Centers for Therapeutic Innovation. Lean how to position your TTO as a partner of choice for pharma collaborations!
Topics will include:
- The changing role of academic research in therapeutic development
- Your assets: greater than the sum of your patent portfolio
- New support at government level for translational medicine initiatives
- Other non-traditional catalysts for partnerships, e.g. disease foundations
- Internal development funds
- Is academia becoming the epicenter for drug development?
- Defining the opportunity that academic partnerships represent for pharmaceutical companies. What’s the motivation?
- Pharma’s new models for academic partnerships
- Pfizer’s Centers for Therapeutic Innovation (CTI)
- Guiding philosophy and rationale for initiating CTI
- Key aspects of the model:
- Joint Steering Committee structure
- Emphasis on partnership through early clinical development
- Results to date
Meet Your Presenters:
Alex Fayne, Chief Operating Officer, Pfizer’s Centers for Therapeutic Innovation (CTI), is responsible for the business affairs of CTI at Pfizer, a new R&D unit pioneering an entrepreneurial research model in partnership with leading academic medical centers. In this role, he is responsible for managing the group’s relationships with 19 academic medical centers nationwide, overseeing operations across a network of four labs, providing commercial input into portfolio decision-making, and managing the group’s finances and business planning. Alex brings a diversity of experience to the CTI team from several biotech companies. As Director of Corporate Strategy at MedImmune, a Division of AstraZeneca, Alex built the company’s Corporate Strategy team to advise senior management on R&D strategy, financial planning, and portfolio decisions. Previously Alex was a member of the Global Strategic Marketing team at MedImmune, where he provided commercial insight into drug development projects within the respiratory, inflammation, and autoimmunity therapeutic area.
Nurjana Bachman, PhD, Business Development Manager, Technology & Innovation Development Office (TIDO), Children’s Hospital Boston, connects Children’s Hospital investigators with outside industry to create opportunities for partnerships at all stages of research, development, and pre-clinical and clinical investigation. She connects groups with similar R&D objectives and complementary resources and helps to structure partnerships for mutual benefit. Most recently she facilitated Children’s Hospital Boston’s participation in Pfizer’s Centers for Therapeutic Innovation. Nurjana also leads TIDO’s Marketing Team and is responsible for TIDO’s external and internal communications, outreach events, and strategic marketing initiatives as well as the office’s primary and secondary market research performed to evaluate invention disclosures and to package technology opportunities for licensing. Prior to becoming Business Development Manager, Nurjana served as licensing manager at Children’s, licensing technologies from the Departments of Orthopaedics, Vascular Biology, and Cardiology, as well as other areas. In addition to other deals she completed, she licensed a portfolio of technologies from the Department of Orthopaedics that formed the basis of a start-up company developing products to address knee injuries.
This webinar is sponsored by the Merrill Corporation
Merrill Corporation has a cultural, organization-wide discipline in the management and processing of confidential content, and is the leading provider of virtual data room (VDR) solutions. Merrill DataSite is a secure VDR solution that optimizes the due diligence process by providing a highly efficient and secure method for sharing key business information between multiple parties. Learn more by visiting www.datasite.com/lifesciences.